Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04487873
Recruitment Status : Completed
First Posted : July 27, 2020
Last Update Posted : May 13, 2021
Information provided by (Responsible Party):
Merve Firat, Hacettepe University

Brief Summary:
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic

Condition or disease
Covid19 Bronchiectasis

Layout table for study information
Study Type : Observational
Actual Enrollment : 74 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
Actual Study Start Date : July 23, 2020
Actual Primary Completion Date : December 18, 2020
Actual Study Completion Date : January 31, 2021

Resource links provided by the National Library of Medicine

Having been diagnosed with non-cystic fibrosis bronchiectasis
Healthy individuals
Healthy individuals without chronic disease

Primary Outcome Measures :
  1. COVID-19 Phobia [ Time Frame: 5 minutes ]
    COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.

  2. Qol [ Time Frame: 10 minutes ]
    Quality of life was evaluated with Nottingham Health Profile

Secondary Outcome Measures :
  1. Health anxiety [ Time Frame: 10 minutes ]
    Health anxiety was evaluated with Health Anxiety Inventory

  2. Physical activity [ Time Frame: 5 minutes ]
    Physical activity level was evaluated with International Physical Activity Questionnaire - Short Form (IPAQ-SF)

  3. Quality of sleep [ Time Frame: 10 minutes ]
    Quality of sleep was evaluated with Pittsburgh Sleep Quality Index

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.

Inclusion Criteria:

  • Having been diagnosed with non-cystic fibrosis bronchiectasis
  • No acute bronchiectasis exacerbation or infection in the past 2 weeks
  • Volunteering to participate in the research

Exclusion Criteria:

  • Having a cognitive problem
  • Not being literate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04487873

Layout table for location information
Hacettepe University, Faculty of Physical Therapy and Rehabilitation
Ankara, Turkey
Sponsors and Collaborators
Hacettepe University
Layout table for investigator information
Principal Investigator: Merve Firat, MSc Hacettepe University
Study Director: Naciye Vardar-Yagli, PhD Hacettepe University
Study Chair: Deniz İnal-İnce, Professor Hacettepe University
Study Chair: Melda Saglam, PhD Hacettepe University
Study Chair: Ebru Calik-Kütükcü, PhD Hacettepe University
Study Chair: Aslıhan Cakmak, MSc Hacettepe University
Layout table for additonal information
Responsible Party: Merve Firat, Principal Investigator, Hacettepe University Identifier: NCT04487873    
Other Study ID Numbers: GO 20/602
First Posted: July 27, 2020    Key Record Dates
Last Update Posted: May 13, 2021
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Merve Firat, Hacettepe University:
quality of life
health anxiety
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Bronchial Diseases